To improve efficacy and broaden the antigens for a more robust anti-tumor immune response, we isolate TCL from cultured ID8-Defb29/Vegf-a-Luc cells and load it into liposomes—as a model of autologous TCL. The gene discussed is DEFB129; the disease is neoplasm.